Abstract 3152
Background
In the single-arm, open-label, multicentre, international phase II trial (NCT02155647 Part A), metastatic Merkel cell carcinoma (mMCC) patients received second-line or later avelumab 10 mg/kg every two weeks. Health-related quality of life (HRQoL) was assessed using the skin cancer-specific FACT-M and the generic EQ-5D. We report HRQoL results 36 months after enrolment of the last patient with focus on HRQoL deterioration-free survival (QFS) rates.
Methods
HRQoL data were obtained at baseline, week 7, and every 6 weeks until disease progression and/or treatment discontinuation. QFS was defined as the time interval between first dose and HRQoL deterioration event i.e. when a HRQoL domain score (FACT-M/EQ VAS) decreased from baseline equivalent to the minimal important difference (MID) threshold, with no further improvement thereafter. For sensitivity analyses, two thresholds are applied termed as minimum and maximum MID. QFS rates were derived from Kaplan-Meier curves and could be interpreted as the likelihood of a patient to endure a time period without relevant HRQoL deterioration until a certain time point.
Results
Based on the intention-to-treat population (n = 88), QFS rates ranged from 40.6% (FACT-M functional well-being, FWB) to 56.3% (EQ VAS) at 12 months when applying minimum MIDs (Table). At 36 months, rates ranged from 20.7% (FWB) to 37.7% (FACT-M social well-being). When applying the maximum MID, QFS rates ranged from 48.6% to 64.9% at 12 months, and 25.3% to 42.7% at 36 months.Table:
1320P HRQoL deterioration-free survival rates (QFS) by time interval (12, 24, 36 months) based on EQ VAS and FACT-M scores applying (negative) minimum/maximum Minimal Important Difference (MID) thresholds, ITT population (N = 88)
MID thresholds1 (min./max.) | HRQoL deterioration-free survival rates (%) | ||||||
---|---|---|---|---|---|---|---|
Minimum MID | Maximum MID | ||||||
Month 12 | Month 24 | Month 36 | Month 12 | Month 24 | Month 36 | ||
EQ-5D | |||||||
EQ VAS | -7 / -10 | 56.3 | 47.4 | 34.8 | 59.0 | 45.5 | 38.5 |
FACT-M | |||||||
Physical well-being (PWB) | -1 / -3 | 46.7 | 43.0 | 36.4 | 52.6 | 46.1 | 35.8 |
Social/Family well-being (SWB) | -1/ -3 | 44.0 | 37.7 | 37.7 | 49.5 | 49.5 | 40.5 |
Emotional well-being (EWB) | -1 / -3 | 49.2 | 41.0 | 32.8 | 55.9 | 51.2 | 42.7 |
Functional well-being (FWB) | -2 / -4 | 40.6 | 32.6 | 20.7 | 52.8 | 48.5 | 33.6 |
Melanoma subscale (MS) | -2 / -5 | 49.7 | 45.7 | 37.4 | 64.9 | 49.1 | 38.2 |
Melanoma surgery scale (MSS) | -2 / -3 | 51.4 | 51.4 | 36.7 | 48.6 | 48.6 | 34.7 |
Trial Outcome Index (TOI) | -4 / -9 | 50.4 | 38.2 | 31.2 | 61.2 | 42.1 | 32.7 |
FACT-G Total Score | -4 / -8 | 46.8 | 37.7 | 24.0 | 51.7 | 43.4 | 27.6 |
FACT-M Total Score | -5 / -12 | 46.6 | 37.6 | 23.9 | 56.9 | 39.7 | 25.3 |
Published in Bharmal, et al. (2017). "Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma." Health Qual Life Outcomes 15(1): 247. Legend: HRQoL=Health-Related Quality of Life; QFS=HRQoL deterioration-free survival rate; MID=Minimal Important Difference; ITT=Intention-to-treat population; VAS=visual analogue scale; EQ VAS=VAS of the EQ-5D questionnaire
Conclusions
As expected, QFS rates decreased over time; however, in the context of an aggressive cancer such as mMCC, various HRQoL domains show promising QFS rates suggesting a substantial proportion of patients reported stable or improved HRQoL on treatment with avelumab across time points, aligned with the clinical efficacy results throughout the long study follow-up of over 36 months.
Clinical trial identification
NCT02155647.
Editorial acknowledgement
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
This study was sponsored by Merck Healthcare KGaA, Darmstadt, Germany, and is part of an alliance between Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY, USA.
Disclosure
S.P. D’Angelo: Advisory / Consultancy: Incyte; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Nektar; Advisory / Consultancy: Amgen; Advisory / Consultancy, Travel / Accommodation / Expenses: EMD Serono; Advisory / Consultancy: GSK; Advisory / Consultancy: ImmuneDesign; Travel / Accommodation / Expenses: Adaptimmune. S. Nolte: Full / Part-time employment, Employee of ICON plc, which is a paid consultant to the study sponsor: ICON plc. M. Schlichting: Full / Part-time employment: Merck Healthcare KGaA. M. Henry-Szatkowski: Full / Part-time employment, Employee of ICON plc, which is a paid consultant to the study sponsor: ICON plc. M. Hennessy: Full / Part-time employment: EMD Serono, Inc. M. Bharmal: Full / Part-time employment: Merck Healthcare KGaA.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract